Uploaded November 2026 | Updated November 2026, 16 hours ago
The FDA just told Novo Nordisk and Eli Lilly to update warning labels on their GLP-1 and Trizepatide medications for weight loss and diabetes. It comes after credible reports of sudden blindness from a rare condition.
——————————
Edited by: Christian Meeks
Writing: Brian Espinoza, Philip DeFranco
————————————
#PhilipDeFranco #GLP1 #Fitness
The FDA just told Novo Nordisk and Eli Lilly to update warning labels on their GLP-1 and Trizepatide medications for weight loss and diabetes. It comes after credible reports of sudden blindness from a rare condition.
——————————
Edited by: Christian Meeks
Writing: Brian Espinoza, Philip DeFranco
————————————
#PhilipDeFranco #GLP1 #Fitness










